Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Alphabet Inc. | 16.56M | $61.0M | 9.16% | -- | 2026-06-30 |
| BlackRock, Inc. | 9.60M | $35.0M | 5.31% | +1.10M | 2026-06-30 |
| ARK Investment Management LLC | 8.35M | $30.0M | 4.62% | +2.10M | 2026-06-30 |
| State Street Corp | 7.58M | $27.0M | 4.19% | +1.23M | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 5.24M | $19.0M | 2.90% | -244.6K | 2026-06-30 |
| Vanguard Capital Management LLC | 4.52M | $16.0M | 2.50% | +48.5K | 2026-06-30 |
| Balyasny Asset Management L.P. | 3.97M | $14.0M | 2.20% | -154.3K | 2026-06-30 |
| Goldman Sachs Group Inc | 3.43M | $12.0M | 1.90% | +2.46M | 2026-06-30 |
| Casdin Capital, LLC | 3.17M | $11.0M | 1.75% | -- | 2026-06-30 |
| Woodline Partners LP | 3.00M | $11.0M | 1.66% | +591 | 2026-06-30 |
